12:00 AM
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Rizatriptan regulatory update

RedHill Biopharma said FDA accepted for review an NDA for RHB-103 to treat acute migraine. The PDUFA date is Feb. 3, 2014. The NDA was submitted under...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >